BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
By Stephen Nakrosis
BeiGene on Thursday said the Food and Drug Administration approved Tevimbra to treat certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma, or ESSC.
The company said this was the first U.S. indication for Tevimbra, or tislelizumab-jsgr. The treatment will be available in the U.S. in the second half of this year, BeiGene said.
The FDA is reviewing biologics license applications for tislelizumab "as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC and patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma," BeiGene said.
Tislelizumab has been approved for certain patients with advanced or metastatic ESCC after prior chemotherapy. It received a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency earlier this year to treat non-small cell lung cancer across three indications, the oncology company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 14, 2024 17:22 ET (21:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing